Ambrosy, A. P. et al. (2019) Burden of medical co-morbidities and benefit from surgical revascularization in patients with ischaemic cardiomyopathy. European Journal of Heart Failure, 21(3), pp. 373-381. (doi: 10.1002/ejhf.1404) (PMID:30698316)
|
Text
180105.pdf - Accepted Version 1MB |
Abstract
Aims: The landmark STICH trial found that surgical revascularization compared to medical therapy alone improved survival in patients with heart failure (HF) of ischaemic aetiology and an ejection fraction (EF) ≤ 35%. However, the interaction between the burden of medical co‐morbidities and the benefit from surgical revascularization has not been previously described in patients with ischaemic cardiomyopathy. Methods and results: The STICH trial (ClinicalTrials.gov Identifier: NCT00023595) enrolled patients ≥ 18 years of age with coronary artery disease amenable to coronary artery bypass grafting (CABG) and an EF ≤ 35%. Eligible participants were randomly assigned 1:1 to receive medical therapy (MED) (n = 602) or MED/CABG (n = 610). A modified Charlson co‐morbidity index (CCI) based on the availability of data and study definitions was calculated by summing the weighted points for all co‐morbid conditions. Patients were divided into mild/moderate (CCI 1–4) and severe (CCI ≥ 5) co‐morbidity. Cox proportional hazards models were used to evaluate the association between CCI and outcomes and the interaction between severity of co‐morbidity and treatment effect. The study population included 349 patients (29%) with a mild/moderate CCI score and 863 patients (71%) with a severe CCI score. Patients with a severe CCI score had greater functional limitations based on 6‐min walk test and impairments in health‐related quality of life as assessed by the Kansas City Cardiomyopathy Questionnaire. A total of 161 patients (Kaplan–Meier rate = 50%) with a mild/moderate CCI score and 579 patients (Kaplan–Meier rate = 69%) with a severe CCI score died over a median follow‐up of 9.8 years. After adjusting for baseline confounders, patients with a severe CCI score were at higher risk for all‐cause mortality (hazard ratio 1.44, 95% confidence interval 1.19–1.74; P < 0.001). There was no interaction between CCI score and treatment effect on survival (P = 0.756). Conclusions: More than 70% of patients had a severe burden of medical co‐morbidities at baseline, which was independently associated with increased risk of death. There was not a differential benefit of surgical revascularization with respect to survival based on severity of co‐morbidity.
Item Type: | Articles |
---|---|
Additional Information: | This work was supported by grants U01HL69015, U01HL69013, and RO1HL105853 from the National Institutes of Health/National Heart, Lung, and Blood Institute (Bethesda, MD). |
Status: | Published |
Refereed: | Yes |
Glasgow Author(s) Enlighten ID: | Cleland, Professor John |
Authors: | Ambrosy, A. P., Stevens, S. R., Al-Khalidi, H. R., Rouleau, J. L., Bouabdallaoui, N., Carson, P. E., Adlbrecht, C., Cleland, J. G.F., Dabrowski, R., Golba, K. S., Pina, I. L., Sueta, C. A., Roy, A., Sopko, G., Bonow, R. O., and Velazquez, E. J. |
Subjects: | R Medicine > R Medicine (General) |
College/School: | College of Medical Veterinary and Life Sciences > School of Health & Wellbeing > Robertson Centre |
Journal Name: | European Journal of Heart Failure |
Publisher: | Wiley |
ISSN: | 1388-9842 |
ISSN (Online): | 1879-0844 |
Published Online: | 30 January 2019 |
Copyright Holders: | Copyright © 2019 The Authors and European Society of Cardiology |
First Published: | First published in European Journal of Heart Failure 21(3):373-381 |
Publisher Policy: | Reproduced in accordance with the publisher copyright policy |
University Staff: Request a correction | Enlighten Editors: Update this record